Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Thursday 01 December, 2016

AstraZeneca PLC

Block listing Interim Review

RNS Number : 7410Q
AstraZeneca PLC
01 December 2016
 

1 December 2016 16:00

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 1 DECEMBER 2016

 

Name of applicant:

ASTRAZENECA PLC

Name of scheme:

ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME

Period of return:

From:

31 MAY 2016

To:

30 NOVEMBER 2016

Balance of unallotted securities under scheme(s) from previous return:

4,065,743

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

478,408

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

3,587,335

 

Name of contact:

MARTIN BENNETT

Telephone number of contact:

07825 530066

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

 

Media Enquiries

 

 

 

 

 

Neil Burrows

 

UK/Global

 

+44 203 749 5637

 

Vanessa Rhodes

 

UK/Global

 

+44 203 749 5736

 

Karen Birmingham

 

UK/Global

 

+44 203 749 5634

 

Rob Skelding

 

UK/Global

 

+44 203 749 5821

 

Jacob Lund

 

Sweden

 

+46 8 553 260 20

 

Michele Meixell

 

US

 

+1 302 885 2677

 




Investor Relations



Thomas Kudsk Larsen

 

 

 

+44 203 749 5712

 

Craig Marks

 

Finance, Fixed Income, M&A

 

+44 7881 615 764

 

Henry Wheeler

 

Oncology

 

+44 203 749 5797

 

Mitchell Chan

 

Oncology

 

+1 240 477 3771

 

Lindsey Trickett

 

Cardiovascular & Metabolic Diseases

 

+1 240 543 7970

 

Nick Stone

 

Respiratory

 

+44 203 749 5716

 

Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

US toll free


+1 866 381 7277

 

Adrian Kemp

Company Secretary, AstraZeneca PLC

 

 

 

-ENDS-

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRFSFFIFFMSEFE

a d v e r t i s e m e n t